PDCD1 and melanoma: Analysis of pre-treatment blood samples from 188 patients with melanoma undergoing PD-1 therapy revealed a median survival discrepancy of > 4 years between patients with a LAG+ immunophenotype and those without (22.2 months vs. 75.8 months).